By ANDREW POLLACK and MICHAEL J. DE LA MERCED
The Swiss drug maker Roche is buying InterMune, a specialist in treatments for breathing diseases, for $8.3 billion, as pharmaceutical firms continue to seek new products to bolster their offerings.
Published: August 24, 2014 at 4:00AM
from NYT Business Day http://ift.tt/1qceiLz
via IFTTT
from WordPress http://ift.tt/1l6a1t5
No comments:
Post a Comment